Cyteir Therapeutics, Inc. (CYT) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
128 Spring Street
Lexington, MA 02421
United States of America (the)
Phone
857 285 4140
Website
Sector
Healthcare
Industry
Biotechnology
Employees
46
First IPO Date
June 18, 2021
| Name | Title | Pay | Year Born |
| Markus F. Renschler | President, Chief Executive Officer & Director | 718,620 | 1961 |
| Joseph S. Zakrzewski | Independent Investor & Independent Chairman of the Board | 81,500 | 1962 |
| Kevin Mills | Co-Founder | 0 | N/A |
| David G. Gaiero | Chief Financial Officer & Treasurer | 0 | 1978 |
Cyteir Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to innovating and bringing to market cutting-edge precision oncology medicines. Its flagship compound, CYT-0851, is an novel, orally administered small molecule drug candidate, designed for once-daily dosing. This therapy is currently undergoing Phase I/II clinical evaluations, both as a standalone treatment and in combination with other drugs, targeting a broad range of solid tumors and hematologic malignancies. Furthermore, the company is advancing CYT-1853, another promising candidate in preclinical development for similar oncological indications. Cyteir Therapeutics was established in 2012 and is headquartered in Lexington, Massachusetts.